Suppr超能文献

鉴定肺腺癌的代谢表型及其与肿瘤免疫微环境的关系。

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.

机构信息

Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.

School of Nursing, Anhui Medical University, Hefei, People's Republic of China.

出版信息

Cancer Immunol Immunother. 2021 Oct;70(10):2835-2850. doi: 10.1007/s00262-021-02896-6. Epub 2021 Mar 3.

Abstract

BACKGROUND

Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), causes high mortality around the world. Previous studies have suggested that the metabolic pattern of tumor is associated with tumor response to immunotherapy and patient's survival outcome. Yet, this relationship in LUAD is still unknown.

METHODS

Therefore, in this study, we identified the immune landscape in different tumor subtypes classified by metabolism-related genes expression with a large-scale dataset (tumor samples, n = 2181; normal samples, n = 419). We comprehensively correlated metabolism-related phenotypes with diverse clinicopathologic characteristics, genomic features, and immunotherapeutic efficacy in LUAD patients.

RESULTS

And we confirmed tumors with activated lipid metabolism tend to have higher immunocytes infiltration and better response to checkpoint immunotherapy. This work highlights the connection between the metabolic pattern of tumor and tumor immune infiltration in LUAD. A scoring system based on metabolism-related gene expression is not only able to predict prognosis of patient with LUAD but also applied to pan-cancer. LUAD response to checkpoint immunotherapy can also be predicted by this scoring system.

CONCLUSIONS

This work revealed the significant connection between metabolic pattern of tumor and tumor immune infiltration, regulating LUAD patients' response to immunotherapy.

摘要

背景

肺腺癌(LUAD)是非小细胞肺癌(NSCLC)的一种亚型,在全球范围内导致高死亡率。先前的研究表明,肿瘤的代谢模式与肿瘤对免疫治疗的反应和患者的生存结果有关。然而,这种关系在 LUAD 中尚不清楚。

方法

因此,在这项研究中,我们使用大规模数据集(肿瘤样本,n=2181;正常样本,n=419),根据与代谢相关基因表达分类的不同肿瘤亚型,确定了免疫景观。我们全面关联了代谢相关表型与 LUAD 患者的不同临床病理特征、基因组特征和免疫治疗疗效。

结果

我们证实,激活脂质代谢的肿瘤往往具有更高的免疫细胞浸润和更好的检查点免疫治疗反应。这项工作强调了肿瘤代谢模式与 LUAD 肿瘤免疫浸润之间的联系。基于代谢相关基因表达的评分系统不仅能够预测 LUAD 患者的预后,而且适用于多种癌症。该评分系统还可以预测 LUAD 对检查点免疫治疗的反应。

结论

这项工作揭示了肿瘤代谢模式与肿瘤免疫浸润之间的显著联系,调节了 LUAD 患者对免疫治疗的反应。

相似文献

1
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.
Cancer Immunol Immunother. 2021 Oct;70(10):2835-2850. doi: 10.1007/s00262-021-02896-6. Epub 2021 Mar 3.
2
Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Cancer Immunol Immunother. 2020 Jul;69(7):1293-1305. doi: 10.1007/s00262-020-02546-3. Epub 2020 Mar 18.
7
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Cancer Med. 2020 Sep;9(18):6694-6709. doi: 10.1002/cam4.3324. Epub 2020 Jul 23.
10
Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
Front Immunol. 2022 Sep 27;13:1022149. doi: 10.3389/fimmu.2022.1022149. eCollection 2022.

引用本文的文献

3
Identification and validation of platinum resistance signature in gastric cancer.
Cancer Cell Int. 2025 Apr 13;25(1):141. doi: 10.1186/s12935-025-03777-z.
6
Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer.
Heliyon. 2024 Mar 6;10(6):e27294. doi: 10.1016/j.heliyon.2024.e27294. eCollection 2024 Mar 30.
7
A PANoptosis pattern to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma.
Heliyon. 2024 Feb 27;10(5):e27162. doi: 10.1016/j.heliyon.2024.e27162. eCollection 2024 Mar 15.
8
Ezrin's role in gastric cancer progression: Implications for immune microenvironment modulation and therapeutic potential.
Heliyon. 2024 Feb 28;10(5):e27155. doi: 10.1016/j.heliyon.2024.e27155. eCollection 2024 Mar 15.
9
MicroRNA-124 plays an inhibitory role in cutaneous squamous cell carcinoma cells via targeting SNAI2, an immunotherapy determinant.
Heliyon. 2024 Jan 15;10(3):e24671. doi: 10.1016/j.heliyon.2024.e24671. eCollection 2024 Feb 15.
10
The analysis of cathepsin L that mediates cellular SARS-CoV-2 infection leading to COVID-19 in head and neck squamous cell carcinoma.
Front Immunol. 2023 May 23;14:1156038. doi: 10.3389/fimmu.2023.1156038. eCollection 2023.

本文引用的文献

1
Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Cancer Med. 2020 Aug;9(16):5960-5975. doi: 10.1002/cam4.3240. Epub 2020 Jun 26.
3
Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Thorac Surg Clin. 2020 May;30(2):187-198. doi: 10.1016/j.thorsurg.2020.01.009.
4
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Immune Netw. 2020 Jan 27;20(1):e10. doi: 10.4110/in.2020.20.e10. eCollection 2020 Feb.
5
Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer.
Brief Bioinform. 2021 Mar 22;22(2):2020-2031. doi: 10.1093/bib/bbaa026.
6
Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Transl Oncol. 2020 Mar;13(3):100738. doi: 10.1016/j.tranon.2019.12.010. Epub 2020 Feb 27.
7
Lung Cancer 2020: Epidemiology, Etiology, and Prevention.
Clin Chest Med. 2020 Mar;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001.
8
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.
Nat Rev Urol. 2020 Feb;17(2):77-106. doi: 10.1038/s41585-019-0263-6. Epub 2020 Jan 17.
9
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.
Cell. 2019 Sep 19;179(1):236-250.e18. doi: 10.1016/j.cell.2019.08.012. Epub 2019 Sep 5.
10
The influence of microenvironment on tumor immunotherapy.
FEBS J. 2019 Nov;286(21):4160-4175. doi: 10.1111/febs.15028. Epub 2019 Aug 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验